PIKFYVE and prostate carcinoma: These results, together with the recent identification of one selective inhibitor of PIP5Kα that efficiently inhibits advanced prostate cancer progression (112), indicate that the investigation of PIP5K functions may open up new avenues to novel interesting therapeutic targets for several disorders.